Semnur Pharmaceuticals Issues Going Concern Warning, Terminates $120M Financing, and Defaults on Promissory Notes
SMNR sits 33% above its 52-week low of $4.5.
Summary
Semnur Pharmaceuticals faces severe liquidity issues, issuing a going concern warning after terminating $120 million in planned financing and defaulting on promissory note payments, alongside significantly increased operating losses.
Key Events · Financing and Capital Events · SMNR
-
Going Concern Warning Issued
Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year, with cash and cash equivalents of only $0.1 million as of March 31, 2026.
-
Terminated $120 Million in Planned Financing
The company terminated a $20 million PIPE Securities Purchase Agreement and a $100 million Bitcoin Securities Purchase Agreement on April 20, 2026, losing $120 million in anticipated funding.
-
Defaults on Promissory Note Payments
Semnur failed to make scheduled Q1 2026 installment payments on the Sponsor Note ($134k), Denali Underwriter Note ($150k), and FutureTech Note ($170k), totaling $0.454 million in missed payments. Accrued interest on the Sponsor Note is $40k.
-
Worsening Financial Performance
Net loss for the three months ended March 31, 2026, significantly increased to $4.6 million from $0.7 million in the prior year period. Cash used in operating activities rose to $2.7 million from $0.4 million.
Analysis · SMNR · Life Sciences
Semnur Pharmaceuticals has disclosed substantial doubt about its ability to continue as a going concern, citing critically low cash reserves of $0.1 million and significant operating losses. This dire financial outlook is exacerbated by the termination of two key financing agreements, a $20 million PIPE SPA and a $100 million Bitcoin SPA, which would have provided $120 million in much-needed capital. Furthermore, the company has defaulted on scheduled payments for several promissory notes, underscoring its severe liquidity crisis. The combination of these factors presents a highly negative and uncertain future for the company.
At the time of this filing, SMNR was trading at $5.99 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.50 to $23.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.